Pacira BioSciences (NASDAQ:PCRX) Posts Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Pacira BioSciences (NASDAQ:PCRX) released its quarterly earnings results on Thursday. The company reported $0.57 earnings per share for the quarter, missing the consensus estimate of $0.85 by ($0.28), FiscalAI reports. Pacira BioSciences had a net margin of 0.97% and a return on equity of 10.16%. The company had revenue of $196.87 million during the quarter, compared to analyst estimates of $201.93 million. During the same quarter last year, the company earned $0.91 EPS. The firm’s quarterly revenue was up 5.1% compared to the same quarter last year.

Here are the key takeaways from Pacira BioSciences’ conference call:

• EXPAREL momentum — Q4 EXPAREL sales were $155.8M, full‑year revenue was $726M, management reports durable H2 volume growth and >100M lives covered outside the surgical bundle (≈110M early 2026), and 2026 EXPAREL guidance is $600M–$620M.
• IP/exclusivity strengthened — Pacira announced a volume‑limited settlement with Fresenius providing EXPAREL runway visibility through 2039 and expanded its patent estate to 21 patents across two families.
• Pipeline entering a data‑rich phase — lead HCAd program PCRX‑201 (Phase 2 Part A top‑line data expected year‑end; Part B enrollment ~mid‑year), PCRX‑2002 in‑licensed with a Phase 2 for bunionectomy planned, and upcoming interim/readouts for ZILRETTA and iovera°.
• Margin and manufacturing gains — Q4 non‑GAAP gross margin improved to 80% from better yields at new 200L EXPAREL facilities; company targets a ~5 percentage‑point margin improvement vs 2024 and guides 77%–79% gross margin for 2026.
• Rising near‑term costs — Q4 non‑GAAP R&D rose to $34.4M (including a $5M upfront for PCRX‑2002) and SG&A to $91.9M (impacted by BD due diligence and litigation); management expects higher R&D and SG&A in 2026 while advancing the 5×30 strategy.

Pacira BioSciences Stock Performance

Shares of Pacira BioSciences stock traded down $0.68 during trading on Friday, hitting $21.91. 2,479,452 shares of the stock were exchanged, compared to its average volume of 695,725. Pacira BioSciences has a 1-year low of $18.80 and a 1-year high of $27.64. The company has a current ratio of 5.26, a quick ratio of 3.78 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $942.57 million, a price-to-earnings ratio of 146.07 and a beta of 0.24. The company has a fifty day moving average price of $22.65 and a 200-day moving average price of $23.85.

Insider Activity at Pacira BioSciences

In other news, SVP Lauren Riker sold 4,000 shares of Pacira BioSciences stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $20.81, for a total transaction of $83,240.00. Following the transaction, the senior vice president owned 52,313 shares in the company, valued at approximately $1,088,633.53. The trade was a 7.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Shawn Cross sold 9,104 shares of the firm’s stock in a transaction dated Wednesday, December 10th. The stock was sold at an average price of $25.14, for a total value of $228,874.56. Following the transaction, the chief financial officer owned 56,250 shares of the company’s stock, valued at $1,414,125. This trade represents a 13.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 30,416 shares of company stock worth $744,315 in the last 90 days. Corporate insiders own 6.40% of the company’s stock.

Institutional Investors Weigh In On Pacira BioSciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Balyasny Asset Management L.P. lifted its position in shares of Pacira BioSciences by 36.1% during the 2nd quarter. Balyasny Asset Management L.P. now owns 2,130,733 shares of the company’s stock worth $50,925,000 after buying an additional 565,288 shares in the last quarter. Goldman Sachs Group Inc. lifted its stake in Pacira BioSciences by 49.9% in the first quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company’s stock valued at $27,454,000 after purchasing an additional 367,869 shares during the last quarter. Marshall Wace LLP purchased a new stake in Pacira BioSciences in the second quarter worth $4,550,000. First Trust Advisors LP lifted its position in shares of Pacira BioSciences by 1,838.9% during the 4th quarter. First Trust Advisors LP now owns 188,889 shares of the company’s stock valued at $4,888,000 after buying an additional 179,147 shares during the last quarter. Finally, Two Sigma Investments LP increased its holdings in Pacira BioSciences by 118.1% in the 3rd quarter. Two Sigma Investments LP now owns 232,994 shares of the company’s stock worth $6,004,000 after acquiring an additional 126,152 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

More Pacira BioSciences News

Here are the key news stories impacting Pacira BioSciences this week:

• Positive Sentiment: Record EXPAREL sales — Pacira said EXPAREL delivered its strongest fourth-quarter performance in three years, driven by 7% volume growth, signaling solid demand for its core product. GlobeNewswire Release
• Neutral Sentiment: Company provided FY-2026 revenue guidance of $745.0 million to $770.0 million (versus consensus ~$766.9M); range implies growth but sits slightly below the consensus midpoint, leaving interpretation mixed for investors. Guidance Detail
• Neutral Sentiment: Full earnings materials and call resources are available (earnings press release, slide deck and call transcripts), useful for investors wanting management commentary on margin drivers and expense cadence. Slide Deck Earnings Call Transcript
• Negative Sentiment: Earnings and revenue missed estimates — Pacira reported Q4 EPS of $0.57 vs. consensus $0.85 and revenue of $196.9M vs. $201.9M expected; the EPS shortfall and top-line miss are primary drivers of the negative price reaction. MarketBeat Earnings Summary
• Negative Sentiment: Rising expenses pressured margins — management flagged higher operating costs that reduced net income and contributed to the EPS miss, raising near-term profitability concerns. Zacks Coverage

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Barclays started coverage on shares of Pacira BioSciences in a research note on Tuesday, December 9th. They issued an “equal weight” rating and a $27.00 target price for the company. Truist Financial cut their price target on Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Friday, November 7th. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Friday, January 9th. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a research report on Monday, December 29th. Finally, Wall Street Zen cut Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $30.75.

About Pacira BioSciences

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.